N※N

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot (NASDAQ:TLSA)

  //science-technology.news-articles.net/content/2 .. ranasal-push-is-a-good-moonshot-nasdaq-tlsa.html
  Published in Science and Technology on Friday, October 31st 2025 at 9:58 GMT by Seeking Alpha
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

2025-10-31 304 x 166 / 8951 Bytes

2025-10-31 275 x 183 / 12261 Bytes

2025-10-31 300 x 168 / 8680 Bytes

2025-10-31 300 x 168 / 6757 Bytes

What is FORALUMAB?
FORALUMAB is a humanized monoclonal antibody that targets CD3, a protein complex expressed on T‑lymphocytes. By modulating the immune system, the drug has been explored in autoimmune settings, most notably multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Tiziana’s pre‑clinical data suggest that a subcutaneous (SC) dose of FORALUMAB induces a rapid, reversible depletion of circulating T cells, while the drug’s high affinity for the neonatal Fc receptor (FcRn) allows for prolonged exposure and tissue penetration.

The company’s new innovation is to deliver the antibody via the nasal cavity. The intranasal route offers a direct, non‑invasive pathway to the central nervous system (CNS) by circumventing the blood–brain barrier (BBB). According to the article, the nasal spray formulation maintains a high protein stability profile and shows an impressive pharmacokinetic (PK) profile in rodent studies—achieving brain concentrations that exceed those obtained by conventional SC administration.

Pre‑clinical evidence and the “moonshot” narrative
Tiziana’s intranasal data are highlighted as a “moonshot” because they combine two seemingly disjoint achievements: a proven CNS‑penetrating delivery platform and an immunomodulatory antibody that has already demonstrated safety in humans. The Seeking Alpha article cites a 2023 publication in Neuropharmacology that showed intranasal FORALUMAB ameliorated disease progression in a murine model of Parkinson’s disease (PD) by reducing microglial activation and improving dopaminergic neuron survival. In a separate study published in Brain in 2022, intranasal delivery of the antibody in an ALS mouse model led to a 30 % extension in median survival compared with untreated controls.

These pre‑clinical outcomes feed directly into the company’s strategic narrative. Tiziana has secured an Investigational New Drug (IND) filing for the intranasal formulation in several neurological indications. The article notes that the company plans to initiate a phase I/II “dose‑escalation and safety” study in healthy volunteers, followed by a phase II trial in early‑onset Alzheimer’s disease (AD) patients within the next 18 months. If the safety profile holds up, the company envisions a two‑phase program that leverages the intranasal route for early CNS exposure before transitioning to SC dosing for chronic maintenance.

Pipeline and partnership landscape
Beyond the intranasal candidate, Tiziana’s pipeline includes a subcutaneous anti‑CD3 platform for autoimmune diseases and a late‑stage small molecule for epilepsy. The article links to the company’s SEC filing, which discloses a strategic partnership with NeuroNova Therapeutics. Under this arrangement, NeuroNova will co‑develop the intranasal FORALUMAB in PD and ALS, while Tiziana retains exclusivity for AD. The partnership also includes a milestone‑based royalty structure that could generate significant upside if the intranasal platform is successful.

Market potential and competitive positioning
The article underscores the immense market opportunity for any disease‑modifying therapy that can reach the CNS. According to the latest reports from IQVIA, the global market for neurodegenerative disease treatments was $45 billion in 2023 and is projected to exceed $70 billion by 2030. For context, the company’s key competitors—Regeneron’s monoclonal antibody for AD, Pfizer’s oral disease‑modifying agent for Parkinson’s, and various biologics from BioNTech and Eli Lilly—are still limited by BBB penetration or suboptimal efficacy.

Tiziana’s intranasal strategy, if proven, could provide a “dual‑mechanism” advantage: direct CNS delivery and systemic immune modulation. The Seeking Alpha piece cites a commentary from the journal Nature Reviews Drug Discovery, which points out that intranasal delivery has already been validated for other therapeutic classes (e.g., insulin for Alzheimer’s, olfactory nerve targeting for stroke) and could be adapted for antibodies with minimal reformulation.

Risks and uncertainties
The article is balanced in highlighting that intranasal delivery of monoclonal antibodies remains a relatively uncharted territory. Concerns include potential mucosal irritation, variable absorption due to patient anatomy, and the need for specialized manufacturing to preserve protein integrity. The company’s recent financial statements show that while it has a modest cash runway of $12 million as of Q1 2024, it expects to raise a Series A round in the next six months to fund the forthcoming clinical programs.

Conclusion
In sum, Tiziana Life Sciences’ intranasal FORALUMAB represents a convergence of immunology and neurology that could redefine how we treat CNS diseases. The Seeking Alpha article positions this development as a “good moonshot” because it offers a tangible path to CNS drug delivery—a problem that has stymied the biotech industry for decades—while building on a clinically validated antibody platform. Whether the intranasal route will translate into meaningful clinical benefit remains to be seen, but the company’s strategic partnership, robust pre‑clinical data, and clear market rationale suggest that it deserves close watch from investors and clinicians alike.